Genomic variant prioritization AI market to hit $5.68B by 2030

By AI, Created 5:13 PM UTC, May 18, 2026, /AGP/ – The genomic variant prioritization AI market is projected to grow from $1.76 billion in 2025 to $5.68 billion by 2030, driven by precision medicine, rising genomic data volume and broader AI use in clinical genomics. North America led the market in 2025, while Asia-Pacific is expected to grow fastest through 2030.

Why it matters: - Genomic variant prioritization AI is becoming a core tool for precision medicine because it helps rank genetic variants linked to disease, diagnosis and treatment decisions. - The market’s rapid growth signals more demand for AI systems that can handle large genomic datasets and support clinical interpretation. - The technology matters to drugmakers, researchers and health systems that need faster ways to turn sequencing data into actionable results.

What happened: - The Business Research Company said the genomic variant prioritization AI market will grow from $1.76 billion in 2025 to $2.22 billion in 2026. - The forecast implies a 26.2% CAGR in 2026. - The market is expected to reach $5.68 billion by 2030. - The report says the 2030 forecast reflects a 26.5% CAGR. - The report was published May 15, 2026. - The report covers regions including Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa.

The details: - The market’s earlier growth was driven by adoption of next-generation sequencing, broader access to genomic databases, more rare genetic disorder research, increased bioinformatics activity and lower genome sequencing costs. - Future growth is expected to come from precision medicine demand, deeper AI use in clinical genomics, population-scale genomic initiatives, more pharma and biotech investment and scalable cloud-based analysis platforms. - The report points to five key trends: AI-powered variant filtering, multi-omics integration, clinical-grade interpretation and reporting, automated genomic workflow management, and explainable AI for clinical decision-making. - Genomic variant prioritization AI uses machine learning to identify and rank variants based on sequence features, estimated functional impact, population frequency, evolutionary conservation and clinical or phenotypic data. - The tools are designed to filter large volumes of variants and surface those most relevant for diagnosis, research or therapy selection. - North America held the largest market share in 2025. - Asia-Pacific is expected to be the fastest-growing region over the forecast period.

Between the lines: - The forecast suggests the bottleneck in genomics is shifting from data generation to data interpretation. - Strong precision medicine momentum is helping justify more spending on software that can turn sequencing outputs into treatment-relevant insights. - The emphasis on explainable AI shows that clinical use still depends on transparency, not just model accuracy. - The report cites the Personalized Medicine Coalition, which said the U.S. Food and Drug Administration approved 16 new personalized therapies for rare diseases in 2023, up from six in 2022.

What’s next: - Growth will likely track continued adoption of AI in clinical genomics and broader investment from pharma and biotech. - More cloud-based genomic analysis platforms and automated workflows are expected as labs try to scale variant interpretation. - Regional leadership may stay concentrated in North America, while Asia-Pacific could narrow the gap as genomics research and biotech support expand. - Download the free sample report - View the full report

The bottom line: - Genomic variant prioritization AI is moving from a niche research tool to a fast-scaling part of the precision medicine stack.